NEW YORK (GenomeWeb) – MDxHealth announced today that it has signed a distribution deal for its SelectMDx for Prostate Cancer test in Spain with pharmaceutical company Ferrer.
Under the terms of the five-year exclusive deal, 10 Ferrer sales representatives will sell SelectMDx directly to 1,000 urologists in Spain. Samples will be sent to MDxHealth's laboratory in Nijmegen, the Netherlands for analysis. The agreement takes effect in January 2018.
Additional terms of the deal were not disclosed.
SelectMDx is a noninvasive liquid biopsy method to assess a man's risk for aggressive prostate cancer by measuring two biomarkers in urine. MDxHealth said it believes the Spanish market is a good opportunity for SelectMDx, given the potential 300,000 or more Spanish men with increased PSA levels who may require further testing to see if they could avoid a biopsy.
"As the SelectMDx test is gaining significant momentum to become standard of care, our commitment to deliver its benefits to men with an elevated PSA level around the world continues to grow," MDxHealth CEO Jan Groen said in a statement. "We believe this relationship with Ferrer will make SelectMDx more widely available to urologists and their patients in Spain."
In March, MDxHealth signed a distribution agreement with Lab21 for SelectMDx in the UK.